Kura Oncology Inc Stock Price, News & Analysis

Kura Oncology, Inc. (Nasdaq: KURA) is set to release its second quarter 2020 financial results on August 6, 2020, after U.S. markets close. Management will hold a webcast and conference call at 4:30 p.m. ET to discuss these results and provide a corporate update. Kura focuses on developing precision medicines for cancer with two promising drug candidates: tipifarnib, which targets HRAS mutant head and neck squamous cell carcinoma, and KO-539, aimed at treating acute myeloid leukemia.

Kura Oncology, a clinical-stage biopharmaceutical company, announced its participation in the JMP Securities Hematology & Oncology Forum on June 18, 2020. CEO Troy Wilson will engage in a fireside chat at 10:40 a.m. ET. The virtual event runs from June 18-19, and interested parties can access a live audio webcast via Kura's website, with an archived replay available for 30 days after the event.

Kura's pipeline includes drug candidates targeting cancer pathways, with its lead candidate being tipifarnib for HRAS mutant head and neck squamous cell carcinoma.

Kura Oncology, Inc. (Nasdaq: KURA) announced acceptance of three abstracts for tipifarnib presentation at the ASCO Virtual Scientific Program scheduled for May 29-31, 2020. Highlights include an oral presentation on the drug's single-agent activity in solid tumors with HRAS mutations, featuring data from the RUN-HN Phase 2 trial on HNSCC patients. Tipifarnib, a farnesyltransferase inhibitor, has Fast Track designation for treating HRAS mutant HNSCC, with prior studies indicating durable anti-cancer activity. The abstracts are accessible on ASCO's website.

Kura Oncology (Nasdaq: KURA) announced the successful closing of its public offering of 10,465,000 shares of common stock at $13.75 per share, raising approximately $143.9 million in gross proceeds. This includes the underwriters' full exercise of their option to purchase an additional 1,365,000 shares. The offering was conducted under an effective shelf registration statement filed with the SEC. Kura aims to advance its portfolio of precision medicines for cancer treatment, including its leading candidate, tipifarnib, for HRAS mutant head and neck cancer.

Kura Oncology, a clinical-stage biopharmaceutical company focused on precision medicines for cancer, will present at the BofA Securities Virtual Healthcare Conference from May 12-14, 2020. CEO Troy Wilson is set to speak on May 12 at 3:40 p.m. ET. The company’s advanced drug candidate, tipifarnib, is undergoing a registration-directed trial for HRAS mutant head and neck squamous cell carcinoma. Another candidate, KO-539, is in a Phase 1/2A trial for relapsed/refractory acute myeloid leukemia. A live audio webcast of the presentation will be available on Kura's website.

Kura Oncology (Nasdaq: KURA) has announced a public offering of 9,100,000 shares of common stock priced at $13.75 per share, expected to generate approximately $125.1 million in gross proceeds. The offering includes a 30-day option for underwriters to purchase an additional 1,365,000 shares. Closing is anticipated on May 8, 2020. The offering is conducted under a shelf registration statement filed with the SEC. This initiative aims to support Kura's efforts in advancing precision cancer medicines.

Kura Oncology has announced the commencement of an underwritten public offering of its common stock. The offering is subject to market and other conditions, with the potential for underwriters to purchase an additional 15% of shares. This move follows Kura's effective shelf registration statement, providing for a streamlined public offering process.

SVB Leerink, Cowen, and Credit Suisse are acting as joint bookrunning managers. The exact size and terms of the offering remain uncertain, emphasizing significant market conditions.

Kura Oncology reported Q1 2020 financials, with a net loss of $19.2 million, increasing from $13.9 million in Q1 2019. The company holds $216.9 million in cash, providing operational leverage for upcoming developments. Kura plans to emphasize its farnesyl transferase inhibitor, tipifarnib, for HRAS mutant HNSCC and the menin inhibitor, KO-539, for NPM1-mutant AML. Three abstracts on tipifarnib will be presented at ASCO 2020. Notably, development of the ERK inhibitor, KO-947, has been terminated to focus on more promising programs.